Compositions for attenuating plasmodium incorporating gene containing modified liver stage nucleoprotein (LINUP) and related methods

• Main Authors: KAPPA STEFAN H I, GOSWAMI DHIRAJ, VAUGHAN ANDREW MICHAEL
• Format: Patent
• Language: Chinese; English
• Published: 02.07.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The present disclosure relates to parasites that cause malaria, in particular parasites of Plasmodium species, more particularly parasites of genetically altered Plasmodium species, which can only normally develop to the late stage of the liver phase, but are fully inhibited upon transition to the blood phase or infection of red blood cells. In particular, the inventors have identified genetic alterations that cause stagnation of these parasites at the late stage of liver developmental stage, which are caused by disruption of gene function of the liver stage nucleoprotein (LINUP) gene. This complete liver stage late arrest allows expression of an enhanced array of parasitic antigens throughout the liver stage development process, but prevents access to the blood stage, red blood cell infection, and related signs, symptoms, and pathologies of malaria disease. 本公开涉及引起疟疾的寄生虫，特别是疟原虫物种寄生虫，更特别是经过基因改变的疟原虫物种寄生虫，这些寄生虫只能正常发育到肝脏阶段晚期，但在转变到血液阶段或感染红细胞时被完全抑制。特别是，发明人已经鉴定出引起这些寄生虫停滞在肝脏发育阶段晚期的基因改变，其由肝脏阶段核蛋白(LINUP)基因的基因功能的破坏而导致。